AzTrials
AzTrials

Early MenopauseSG-PRIMENCT07100639

Singapore Population Research on Integrated exposoMe & Early Menopause

An observational study of Early Menopause, run by Institute for Human Development and Potential (IHDP), Singapore.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Brief Summary The goal of this observational study is to learn how environmental factors, lifestyle choices, and social conditions affect the timing of menopause in Asian women aged 40-50 years living in Singapore. Read more about this study

Who is it for?
Ages 40 to 50 years, women onlyHealthy volunteers can take part
Conditions the study is for
Early Menopause
How many people
400 participants
Where
No sites listed yet
Study dates
6 Aug 2025to 1 Apr 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 50 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Women experiencing perimenopausal transition characterized by irregular menstrual patterns and hormonal fluctuations, stratified by age groups (40-45 years and 46-50 years) and ethnicity to ensure representative sampling of Singapore's multi-ethnic population.

Who may be able to join

  • Female participants aged 40-50 years No menstruation for the last 2 months or irregular menstrual cycles in the last 6 months Chinese, Malay, or Indian ethnicity Proficient in English language Planning to reside in Singapore for next 2 years Willing to provide informed consent and comply with study procedures

Who cannot join

  • In menopause (12 consecutive months without menstruation) Currently pregnant or planning to conceive History of bilateral oophorectomy and/or hysterectomy Currently receiving hormone therapy, including estradiol replacement therapy or oral contraceptives Diagnosed with premature ovarian insufficiency before 40 years of age Diagnosis of autoimmune conditions and/or chromosomal abnormalities known to affect ovarian function Diagnosis of severe cognitive impairment and/or mental disorders Received cancer treatment in the past 12 months

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Narasimhan Kothandaraman, Ph.D contact

+65 64074057

Kothandaraman_Narasimhan@sics.-astar.edu.sg

About this study

Official title: From Exposome to Health Outcomes: A Population-Based Approach to Understanding and Mitigating Early Menopause in Singapore's Diverse Communities

Brief Summary

The goal of this observational study is to learn how environmental factors, lifestyle choices, and social conditions affect the timing of menopause in Asian women aged 40-50 years living in Singapore. The main aims of the project are the following:

Read more
  • Do environmental pollutants and lifestyle exposures contribute to earlier menopause in Asian women?
  • What biological changes occur when women are exposed to harmful environmental factors during menopause transition?

Participants will be followed for 18 months and will complete questionnaires about their health history, lifestyle, diet, and environmental exposures. Participants will provide blood, urine, stool, hair, and nail samples for laboratory analysis and undergo basic health assessments including weight, blood pressure, and bone density measurements. Participants will wear activity monitors and air pollution sensors for 7 days and attend follow-up visits at 6 months, 12 months, and 18 months to track changes in their health. This data will be obtained during the baseline visit.

Read the detailed description

Detailed Description

Background and Rationale: Early menopause, defined as cessation of ovarian function before age 45, affects approximately 5-12% of women globally and is associated with increased risks of cardiovascular disease, osteoporosis, and cognitive decline. Growing evidence suggests that environmental exposures, including persistent organic pollutants, air pollution, and endocrine-disrupting chemicals, may accelerate ovarian aging and contribute to earlier menopausal timing. The exposome concept involves the totality of environmental exposures experienced by individuals throughout their lifetimes, including chemical, physical, biological, and social factors.

Study Hypothesis We hypothesize that combined exposure to environmental pollutants, lifestyle factors, and social conditions accelerates biological aging processes and leads to earlier menopause onset in women. These exposome effects are mediated through changes in gene expression patterns, metabolic profiles, and gut microbiome composition, ultimately increasing the risk of adverse health outcomes.

Study Design: This is a prospective observational cohort study employing a longitudinal design with 18-month follow-up. The study integrates comprehensive exposome assessment with multi-omics profiling to investigate the complex relationships between environmental factors and menopausal health outcomes in a multi-ethnic Asian population.

Population and Setting: Four hundred women aged 40-50 years will be recruited from diverse communities across Singapore. Participants must have experienced no menstruation for the last 2 months or irregular menstrual cycles in the last 6 months, be proficient in English, and plan to reside in Singapore for the study duration. The study will include Chinese, Malay, and Indian ethnicities reflecting Singapore's demographic composition.

Data Collection Methods: Exposome characterization includes external environmental monitoring through air pollution assessment, climate data collection, green space quantification, and personal exposure measurement using wearable devices. Biological samples including blood, urine, stool, hair, and nail specimens will undergo multi-omics analysis encompassing metabolomics, lipidomics, epigenetics, transcriptomics, and microbiome profiling. Clinical assessments include anthropometric measurements, blood pressure monitoring, and bone density evaluation.

Analysis Plan: Multi-layered analytical approaches will include exposome-wide association studies, machine learning techniques for predictive modeling, and causal inference methods to examine relationships between exposome factors and menopausal outcomes. Advanced statistical methods will account for the high-dimensional nature of exposome data and temporal relationships between exposures and health outcomes.

Eligibility Criteria

Inclusion Criteria:

  • Female participants aged 40-50 years
  • No menstruation for the last 2 months or irregular menstrual cycles in the last 6 months
  • Chinese, Malay, or Indian ethnicity
  • Proficient in English language
  • Planning to reside in Singapore for next 2 years
  • Willing to provide informed consent and comply with study procedures

Exclusion Criteria:

  • In menopause (12 consecutive months without menstruation)
  • Currently pregnant or planning to conceive
  • History of bilateral oophorectomy and/or hysterectomy
  • Currently receiving hormone therapy, including estradiol replacement therapy or oral contraceptives
  • Diagnosed with premature ovarian insufficiency before 40 years of age
  • Diagnosis of autoimmune conditions and/or chromosomal abnormalities known to affect ovarian function
  • Diagnosis of severe cognitive impairment and/or mental disorders
  • Received cancer treatment in the past 12 months

Target Sample Size 400 participants

Conditions
Early Menopause
Keywords
early menopause, environment, pollution, exposome
Medical subject headings
Primary Ovarian Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07100639
Study groupRoleWhat they receive
SG-PRIMEno interventions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Early menopause

    Measured: 18 months

  2. Time to menopause onset

    • Menopausal symptom severity score using standardized assessment tools

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2025
  2. Study start6 Aug 2025 (estimated)
  3. Primary completion31 Mar 2028 (estimated)
  4. Study completion1 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07100639
Sponsor's protocol ID
2050-50
Other IDs
MOH-001786-00
Acronym
SG-PRIME
Status last verified
Jul 2025
First submitted
27 Jul 2025
Last updated
3 Aug 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Early Menopause, run by Institute for Human Development and Potential (IHDP), Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Narasimhan Kothandaraman, Ph.D (+65 64074057, Kothandaraman_Narasimhan@sics.-astar.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Early menopause (time frame: 18 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in